ICCPP ODM+ Won Two Muse Design Gold Awards, Keeping Leading the Creative Design Trend
15.9.2023 15:00:00 EEST | Business Wire | Press release
Recently, the winners of MUSE Design Awards 2023, known as the Oscar Awards of the design, were announced, and ICCPP ODM+'s Cyclo eco-friendly e-cigarette and SPEEX X1, one of SPEEX dual-coils and screen display series display products, stood out and won Gold Awards of Muse Design from nearly 40,000 works worldwide, thanks to their advanced globalization vision, innovative user-centered design, and sustainable concepts of caring for both human beings and nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904756304/en/
ICCPP ODM+ Won MUSE DESIGN GOLD AWARDS (Photo: Business Wire)
MUSE Design Awards was founded in 2015 by International Awards Associates (IAA), a long-established U.S.-based international design awards association, and is one of the most influential international awards in the field of global creative design. The awards have always been known for their rigorous judging system and high quality standards, aiming to cultivate, promote and recognize excellence in the global design field, and promote the development of the global design industry to a higher level.
ICCPP ODM+ won the two design gold awards in one go in its first competition, which was not only a confirmation of its global leadership in future-oriented innovative product design, concepts and inspirations, but also a recognition of the strength of ICCPP Group's user-centered approach to deepening innovation and empowering the development of the e-atomization industry, and even set a new benchmark for global brands in e-cigarette product design.
It is understood that one of the Gold Award winners, SPEEX X1 is an independent innovative flagship product of the SPEEX heating technology series with high-capacity, dual coil and screen display from ICCPP ODM+, listed in August. It is a unique combination of dual-coil design with dual output working models and SPEEX rocket-like heating technology, and plus the small, rounded, extremely compact and aesthetic design, superimposed on the 0.73-inch oversized e-liquid and power remain screen display, SPEEX X1 achieves a perfect balance among the flavor, vapor, aesthetics and user thinking.
Cyclo, the other winner of Muse Design Gold Awards, is a new 2ml product launched by ICCPP ODM+ at VAPER EXPO UK2023 in May. Considering global trend of low carbon and environmentally friendly concept, coupled with the deep concerns of global users about increasingly serious environmental problems caused by the prevalence of disposable e-cigarettes, as well as the enforce reality of Europe's new Battery Law and some environmental protection acts, ICCPP ODM+ innovatively developed Cyclo, the world's first double environmentally-friendly concept disposable e-cigarettes solution. Through its innovative application of PLA degradable materials, coupled with lead-free and solder-free inner structures, and modularized and fully automated design, as well as the aesthetics of simple, rounded and hand-held shape, and the creative integration of the concepts of user detachable and biodegradable, Cyclo is ahead of the industry to achieve the balance of portability, artistry and recyclability for the users in advance.
While these two award-winning products are just a small microcosm of ICCPP ODM+'s human-centered, and user-first design philosophy. At ICCPP, we believe that design is not just about aesthetics, but should also keep upgrading user experience, meeting user needs and creating a more meaningful connection between people, society and nature. In the future, ICCPP ODM+ will continue to be committed to continuous innovation, to lead the design trend, to create more and more exciting and premium e-cigarette product solutions, and to bring a healthier and happier e-atomized life to vaping enthusiasts around the world.
For more information, please refer to: https://www.iccpp.com/
WARNING: This product contains nicotine which is a highly addictive substance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904756304/en/
Contact information
Media:
Carol, carol@iccpp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom